Cellbricks Therapeutics has secured €10 million in funding, including a €7 million seed round and over €3 million in non-dilutive financing, to advance its biofabricated human tissue implants toward clinical testing. This investment will primarily support the company’s lead adipose tissue implant program, facilitating preclinical animal studies and generating crucial translational data for applications in treating complex soft tissue defects, wound healing, and trauma care.

The significance of this development lies in its potential to provide biological alternatives to synthetic implants used in reconstructive surgeries, such as breast reconstruction. With backing from notable investors including Silicon Roundabout Ventures and Germany’s Federal Agency for Breakthrough Innovation SPRIND, Cellbricks aims to validate its proprietary biofabrication platform, which produces vascularized human tissue implants.

A key takeaway for professionals in the longevity and healthspan research field is the growing emphasis on biofabrication technologies, which could revolutionize regenerative medicine and enhance therapeutic options for age-related tissue degeneration.

Source: longevity.technology